In a recent study published in the BMJ, researchers conducted a phase three, multicenter, randomized controlled trial to evaluate the effect of using angiotensin receptor blockers that disrupt the ...

CHICAGO — Patients with reduced left ventricular ejection fraction who were discharged after being hospitalized for acute MI and took ACE inhibitors or angiotensin receptor blockers had decreased risk ...

Losartan may help stop the epileptic process in certain patients with hypertension. An observational study that analyzed medical records of 2.26 million patients with hypertension found a roughly 30% ...

Angiotensin receptor blockers exhibited potential neuroprotective properties for reducing Parkinson disease (PD) risk in patients with newly diagnosed hypertension. A statistically significant ...

Emerging concerns that common antihypertensive treatment approaches with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) – jointly known as ...

Please provide your email address to receive an email when new articles are posted on . Patients with advanced chronic kidney disease may benefit from use of angiotensin-converting enzyme inhibitors ...

Rotterdam, the Netherlands - Investigators assessing the antiproteinuric effects of the angiotensin 2 receptor blocker (ARB) losartan (Cozaar ®, Merck) have found the drug reduces urinary albumin ...

Despite long-term and adequate ACE inhibition, angiotensin II concentrations return to pretreatment levels or higher. [14,15] Several ACE-independent enzymes have been found to produce angiotensin II.

In the search for treatments for COVID-19, many researchers are focusing their attention on a specific protein that allows the virus to infect human cells. Called the angiotensin-converting enzyme 2, ...

The angiotensin-receptor blocker (ARB) telmisartan ameliorates endothelial dysfunction following drug-eluting stent (DES) implantation better than the calcium-channel blocker amlodipine in ...

A new study published in the journal of Clinical Gastroenterology and Hepatology showed that calcium-channel blockers (CCB) ...

First-line durvalumab with arterial chemotherapy in major portal invaded hepatocellular carcinoma: The phase 2 DurHope study with biomolecular analyses. Comparative diagnostic accuracy and tumor ...